Clinical trials: Urological Manifestations
Overactive Bladder
Drug Use-Results Survey of Betanis Tablets in Japan
This study is to determine the following information. 1. The occurrence of adverse drug reactions in clinical settings. 2. Factors potentially impacting safety, effectiveness, and other aspects.
- Trial name
- NCT01919047
- Testing
- Betanis
- Where
- 8 sites in Japan
- Volunteers
- 10,711 people
- Sponsor
- Astellas Pharma Inc
Nocturia
VA106483 Dose Response in Females
The purpose of this study is to describe the pharmacokinetics and pharmacodynamics of VA106483 in female subjects.
- Trial name
- NCT01171391
- Testing
- VA106483
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
Stress Urinary Incontinence
An Investigation With an Intra-vaginal Device for Stress Urinary Incontinence
This is a prospective, randomized, controlled, two-armed multi-center pre-market trial. Nighty-six (96) subjects will be recruited at sites in Sweden.
- Trial name
- NCT03186651
- Testing
- TVS
- Where
- 4 sites in Sweden
- Volunteers
- 97 people
- Sponsor
- Invent Medic Sweden AB
Nocturia
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
The purpose of this study is to assess psychometric properties (reliability and validity) of the Nocturia Impact (NI) diary. To assess the association between reduction of number of nocturnal voids and the mean changes in NI…
- Trial name
- IMPACT (NCT01552343)
- Testing
- Desmopressin
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder, Overactive Urinary Bladder
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)
The study is designed to investigate the effects of the investigational drug vibegron (MK-4618) compared to placebo on maximum urinary bladder capacity in women with overactive bladder.
- Trial name
- NCT01500382
- Testing
- Vibegron, Tolterodine ER, Prophylactic Antibiotic
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder
Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)
The aim of the study is to determine how well the drug BAY1817080 works in OAB patients with urgency urinary incontinence (UUI), defined as involuntary leakage of urine, accompanied or immediately preceded by a sudden compelling…
- Trial name
- OVADER (NCT04545580)
- Testing
- BAY1817080
- Where
- 28 sites in Australia, Austria and 7 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Lower Urinary Tract Symptoms
Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH
The purpose of the this international, multicenter, randomised, single-blind, parallel group, Phase III study is to demonstrate that a single transrectal ultrasound (TRUS)-guided intraprostatic injection of NX-1207 provides a…
- Trial name
- NCT02003742
- Testing
- NX-1207, Tamsulosin
- Where
- 5 sites in Germany, Italy and 3 more
- Volunteers
- 104 people
- Sponsor
- RECORDATI GROUP
Overactive Bladder
Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence
A pre-market, prospective, non-randomized acute feasibility study for the treatment of patients with urinary incontinence (UI) as a consequence of urinary incontinence.
- Trial name
- NCT03643380
- Testing
- AHLeveeS System
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Neuspera Medical, Inc.
C3G
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol.
- Trial name
- APPEAR-C3G (NCT04817618)
- Testing
- iptacopan
- Where
- 88 sites in United States, Argentina and 17 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Urinary Incontinence, Stress
Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.
SS-RBX will be used to evaluate pharmacodynamic changes in urethral function using a novel methodology
- Trial name
- NCT00141128
- Testing
- SS-RBX
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Pfizer
Urinary Bladder, Overactive
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of YM178 against placebo and tolterodine to treat patients with symptoms of over active bladder.
- Trial name
- Blossom (NCT01604928)
- Testing
- YM178, tolterodine
- Where
- 30 sites in Belgium, Czechia and 4 more
- Volunteers
- 260 people
- Sponsor
- Astellas Pharma Europe B.V.
Hypertension, Diabetes
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and…
- Conditions
- Hypertension, Diabetes, Proteinuria
- Trial name
- TANDEM (NCT00234871)
- Testing
- trandolapril/verapamil, Lotrel (amlodipine/benazepril)
- Volunteers
- 357 people
- Sponsor
- Abbott
Lower Urinary Tract Symptoms
Reliability of Home Uroflowmetery Using a Disposable Digital Device
The FloRite™ device is a disposable urine flow meter, indicated for use in a home setting. The device provides Urofowmetry measurements, similar to clinic's measurements.
- Trial name
- NCT02026674
- Testing
- FloRite
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Flometrica Ltd.
Urge Incontinence, Urinary Retention
Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control
The purpose of this study is assess the long-term safety and effectiveness of the InterStim tined lead using a minimally invasive approach.
- Trial name
- NCT00225966
- Testing
- Device Medtronic InterStim Tined Leads Models 3889 and 3093
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity
The purpose of this study is to evaluate the safety of a new product that uses human gene transfer (called hMaxi-K) when it is given to patients with overactive bladder.
- Trial name
- NCT00495053
- Testing
- hMaxi-K
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Urovant Sciences GmbH
Nocturia
Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia
The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
- Trial name
- NCT01259128
- Testing
- SER120 Nasal Spray 500 ng/day, SER120 nasal spray 750 ng/day
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Lower Urinary Tract Symptoms, Overactive Bladder
Tetra-NIRS Clinical Study
The purpose of this evaluation is to validate the previous clinical study results using a Near-Infrared Spectroscopy (NIRS) device, as compared to the conventional urodynamics (UDS) testing.
- Trial name
- NCT00871975
- Testing
- Urodynamics + TETRA - NIRS
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Laborie Medical Technologies Inc.
Arterial Hypertension, Albuminuria
Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
A recent study with the DPP-IV inhibitor Linagliptin showed an improvement in the urinary albumin creatinine ratio in patients with diabetic nephropathy. Gutzwiller et. Al.
- Trial name
- NCT02376075
- Testing
- Linagliptin
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- ikfe-CRO GmbH
Urinary Incontinence
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
To evaluate efficacy of tolterodine extended release formulation compared with immediate release formulation in subjects with symptoms of overactive bladder
- Trial name
- NCT00139724
- Testing
- tolterodine extended release capsule
- Where
- 7 sites in China
- Volunteers
- 260 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer